KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Loans and Notes Receivables (2016 - 2017)

Travere Therapeutics (TVTX) has disclosed Loans and Notes Receivables for 3 consecutive years, with $47.2 million as the latest value for Q1 2017.

  • For the quarter ending Q1 2017, Loans and Notes Receivables changed 0.0% year-over-year to $47.2 million, compared with a TTM value of $47.2 million through Mar 2017, changed 0.0%, and an annual FY2016 reading of $46.8 million, changed 0.0% over the prior year.
  • Loans and Notes Receivables was $47.2 million for Q1 2017 at Travere Therapeutics, up from $46.8 million in the prior quarter.
  • Across five years, Loans and Notes Receivables topped out at $47.5 million in Q2 2016 and bottomed at $46.5 million in Q3 2015.
  • Average Loans and Notes Receivables over 3 years is $46.9 million, with a median of $46.8 million recorded in 2015.
  • Peak annual rise in Loans and Notes Receivables hit 0.0% in 2016, while the deepest fall reached 0.0% in 2016.
  • Year by year, Loans and Notes Receivables stood at $46.8 million in 2015, then changed by 0.0% to $46.8 million in 2016, then rose by 0.69% to $47.2 million in 2017.
  • Business Quant data shows Loans and Notes Receivables for TVTX at $47.2 million in Q1 2017, $46.8 million in Q4 2016, and $46.5 million in Q3 2016.